PharmaResources (Shanghai) Co., Ltd. (SHE:301230)
China
· Delayed Price · Currency is CNY 41.95
+0.35 (0.84%)
At close: Apr 29, 2026
SHE:301230 Revenue
PharmaResources (Shanghai) had revenue of 172.29M CNY in the quarter ending March 31, 2026, with 1.69% growth. This brings the company's revenue in the last twelve months to 691.21M, up 18.52% year-over-year. In the year 2025, PharmaResources (Shanghai) had annual revenue of 688.35M with 26.43% growth.
Revenue (ttm)
691.21M
Revenue Growth
+18.52%
P/S Ratio
8.35
Revenue / Employee
688.45K
Employees
1,085
Market Cap
5.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 688.35M | 143.88M | 26.43% |
| Dec 31, 2024 | 544.47M | 54.75M | 11.18% |
| Dec 31, 2023 | 489.72M | 10.83M | 2.26% |
| Jan 1, 2023 | 478.88M | 30.67M | 6.84% |
| Jan 1, 2022 | 448.21M | 165.22M | 58.39% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.26B |
| Shenzhen Weiguang Biological Products | 1.26B |
| Lifecome Biochemistry | 502.95M |
| Shouyao Holdings (Beijing) Co., LTD. | 34.67M |
| Kexing Biopharm | 1.53B |
| Wuhan Hvsen Biotechnology | 1.68B |
| Beijing Konruns Pharmaceutical | 917.99M |
| Innovita Biological Technology | 422.03M |